BOSTON, Sept. 6 /PRNewswire/ -- Surface Logix Inc. announced today the appointment of W. James O’Shea to the Company’s Board of Directors. Currently Mr. O’Shea is President and Chief Operating Officer at Sepracor Inc. in Marlborough, MA. As a member of the Board, Mr. O’Shea will provide strategic advice on the commercialization and partnering activities of the Company’s pipeline of new drugs.
“I am extremely pleased to welcome Jim to the Surface Logix Board,” said Jim Mahoney, President and CEO of Surface Logix. “The breadth of his commercial development experience in the pharmaceutical industry is exactly what our company needs as we continue to progress our assets through clinical development and consider our partnering options.”
Prior to joining Sepracor in October 1999, Mr. O’Shea was Senior Vice President of Sales and Marketing and Medical Affairs for Zeneca Pharmaceuticals, a business unit of Zeneca Inc. While at Zeneca, he also held several management positions of increasing responsibility in international sales and marketing in the U.S. and U.K. Mr. O’Shea is an executive Board member and past Chairman of the National Pharmaceutical Council and is also a Board member of CollaGenex.
Mr. O’Shea is a graduate of Liverpool Lord Byron University. He received an Honors Degree in Applied Physics from the Institute of Physics.
About Surface Logix Inc.
Surface Logix Inc. uses its expertise in biophysical chemistry to create new small molecule drugs that are optimized to meet the challenges of human physiology. The company is advancing multiple internal programs focused primarily on cardiovascular, metabolic, inflammatory and fibrotic diseases. For more information, please visit http://www.surfacelogix.com.
Contact: David H. Donabedian, Ph.D. Vice President, Business Development 617.746.8520
Media: Kari Watson MacDougall Biomedical Communications Inc. 508.647.0209
Source: Surface Logix Inc.
